If you have been searching for alternatives to knee replacement or looking into orthobiologic options for joint pain, you have probably come across terms like “microfragmented fat,” “Lipogems,” or “fat-based stem cell injections.” These phrases show up in clinic marketing materials, social media posts, and patient testimonials, often with dramatic before-and-after claims. But what does the actual clinical evidence say?
TLDR Microfragmented adipose tissue, commonly called MFAT, is a specific way of processing fat tissue that has been studied in randomized clinical trials for knee osteoarthritis, wound healing, and other conditions. Some of those trials show genuinely interesting results. Others show outcomes no better than a saline placebo. None of them has led to FDA approval.
This article explains what MFAT is, how it differs from other adipose-based products, what the randomized trial data actually show (both positive and negative), how FDA regulations apply, and how MFAT relates to adipose tissue banking. The goal is to give patients and providers an honest, evidence-based summary, not to recommend or discourage any specific procedure.
Important Disclaimers
Save My Fat does not provide, administer, or sell MFAT procedures. Save My Fat is an adipose tissue banking service that preserves fat for potential future use in regulated pathways. MFAT is not FDA-approved for knee osteoarthritis, tendon injuries, wound healing, or any other medical condition. Banking adipose tissue does not guarantee access to MFAT or any other treatment, clinical trial, or therapeutic product. All content on this page is for educational purposes only and does not constitute medical advice. Patients should discuss all treatment decisions with their own licensed healthcare providers.
What Is Microfragmented Adipose Tissue and How Is It Prepared?
MFAT is adipose (fat) tissue that has been mechanically processed into small tissue fragments using a closed-system device. During the procedure, a physician harvests a small volume of fat through liposuction, typically from the abdomen or flanks. That fat is then pushed through a series of filters and washed with saline inside a sealed device, which breaks it into smaller clusters while removing oil, blood, and excess fluid. The result is a concentrated tissue product containing small adipose fragments along with the cells that naturally reside in fat, including pericytes, stromal cells, and other supportive cell populations.
This process is different from three other adipose-based approaches that patients often hear about.
Simple fat grafting uses larger pieces of harvested fat, usually for cosmetic volume restoration or reconstructive purposes. The fat lobules are larger and minimally processed.
Stromal vascular fraction (SVF) is produced by enzymatically digesting fat tissue with collagenase to isolate a concentrated cell population. FDA considers this enzymatic step “more than minimal manipulation,” which places SVF into the drug and biologic regulatory pathway. For a deeper comparison, see our overview of stem cell research areas.
Cultured adipose-derived stem cells (ADSCs) are grown and expanded in a laboratory over days or weeks. This is clearly more than minimal manipulation and requires full biologic approval under an IND or BLA.
One detail that matters for patients considering banking: MFAT procedures in clinical trials use same-day harvest and injection. The fat is collected, processed, and injected during a single visit. These protocols do not use previously stored or banked tissue.
Where MFAT Is Being Studied: Orthopedic Trials
The largest body of MFAT evidence comes from randomized controlled trials in knee osteoarthritis. Several key findings have emerged, and they tell a mixed story.
MFAT compared to PRP. Multiple RCTs have compared single injections of MFAT to platelet-rich plasma (PRP) for symptomatic knee OA. In a Level 1 trial of 118 patients followed for 24 months, both MFAT and PRP groups showed significant improvements in pain and function scores, with no consistent superiority of one treatment over the other at any time point. A separate RCT of 71 patients at 12 months confirmed similar findings: both groups exceeded the minimal clinically important difference for pain improvement, with no statistically significant difference between treatments.
MFAT compared to saline and corticosteroid. A partially blinded RCT of 75 patients randomized participants to MFAT, corticosteroid injection, or saline control. At one year, the MFAT group showed greater and more durable improvements in KOOS pain and function scores compared to saline. The corticosteroid group improved early but returned toward baseline by 12 months, while MFAT maintained its effect. This was classified as Level II evidence with a moderate sample size.
MFAT combined with arthroscopic debridement. An RCT of 78 patients compared arthroscopic debridement alone to debridement plus MFAT injection in patients with Kellgren-Lawrence grade 3 to 4 knee OA. The combination group showed better functional scores at 6 and 24 months, along with improved MRI T2-mapping findings in the cartilage. However, this was an active-control design without a sham arm.
MFAT no better than saline at two years. A blinded randomized trial published in 2025 found that a single MFAT injection was not superior to saline placebo at two-year follow-up. This result is important because it demonstrates that positive short-term findings do not always hold up over longer periods and that placebo responses in OA injection trials can be substantial.
Across all of these studies, no trial has demonstrated that MFAT modifies the structural progression of osteoarthritis. Cartilage regrowth remains unproven. Sample sizes range from roughly 70 to 120 patients, and most trials follow patients for one to two years. These are useful data points, but they are not the large, multi-center, long-term confirmatory trials that regulatory agencies require for product approval.
MFAT Beyond Joints: The Diabetic Foot Trial
MFAT has also been studied outside orthopedics. The most notable example is the MiFrAADiF trial, a randomized controlled study (NCT03276312) that evaluated MFAT injection at diabetic minor amputation stumps. In the trial, 114 patients were randomized to receive either local MFAT injection or standard wound care following a minor foot amputation.
At six months, approximately 80 percent of the MFAT-treated wounds had healed compared to 46 percent in the standard care group. No treatment-related serious adverse events were documented. The trial also reported shorter hospital stays and improved physical quality-of-life scores in the MFAT group.
These results are encouraging, but context matters. The MiFrAADiF trial was conducted at a single center in Italy, was not blinded, and followed patients for only six months. The findings apply specifically to diabetic minor amputation wound care, not to joint disease, systemic conditions, or other wound types. MFAT is not an approved treatment for diabetic foot complications in the United States or elsewhere.
What Systematic Reviews Say About MFAT
Two types of systematic reviews help frame the broader MFAT evidence.
A 2025 systematic review and meta-analysis specifically comparing MFAT to PRP across six RCTs concluded that both intra-articular injections provided clinically meaningful improvements in pain and function up to 12 months. Safety profiles were comparable between the two approaches. However, neither treatment showed consistent superiority over the other across all outcomes and time points.
A broader meta-analysis of adipose-derived cell therapies for knee OA, which included studies using ADSCs, SVF, and some MFAT protocols, found that cell-based treatments improved WOMAC scores over time and appeared safe. The authors noted significant heterogeneity across included studies, small sample sizes, and a clear need for large, independently funded trials before clinical recommendations could be made.
These reviews reinforce an important point: a meta-analysis showing statistical improvement does not mean a product is approved, appropriate for every patient, or superior to established treatments like physical therapy, weight management, or joint replacement when indicated. For more context on what research areas are being explored with adipose-derived cells, see our condition-specific pages.
How FDA and Regulators View MFAT
Understanding MFAT regulation requires two key concepts from FDA’s HCT/P framework: minimal manipulation and homologous use.
Minimal manipulation means processing that does not alter the original relevant characteristics of the tissue. For structural tissues like fat, this means not changing the tissue’s physical properties. MFAT’s mechanical processing, which breaks fat into smaller fragments without enzymes, is sometimes argued to meet this criterion. However, this remains a point of regulatory debate depending on the specific device and processing method used.
Homologous use means the tissue performs the same basic function in the recipient as it did in the donor. Adipose tissue naturally provides cushioning, insulation, and structural support. When MFAT is injected into an osteoarthritic knee to reduce pain or improve cartilage health, it is being used for a purpose that does not match its original biological function. As one regulatory analysis has detailed, this constitutes non-homologous use, which moves the product out of the simpler HCT/P pathway and into full drug and biologic regulation.
The practical result: even if MFAT’s mechanical processing could be considered minimally manipulated, using it for osteoarthritis or wound healing likely fails the homologous use requirement. That means these uses should be regulated under IND/BLA pathways, not marketed as routine office procedures. The FDA has issued consumer alerts about unapproved regenerative medicine products, including adipose-based offerings.
There are no FDA-approved MFAT products for knee osteoarthritis, diabetic foot ulcers, tendon injuries, or any systemic disease.
MFAT vs. Adipose Banking: What Is the Relationship?
Patients who have banked their adipose tissue or are considering banking sometimes ask whether their stored fat could later be used for an MFAT procedure. This is an understandable question, but the current answer is clear.
MFAT is a same-day, point-of-care procedure. In every published clinical trial, MFAT is harvested via liposuction, processed in a closed device, and injected during the same visit. The protocols do not include a step where previously frozen tissue is thawed and processed into MFAT.
Adipose banking is long-term preservation. When tissue is banked through a service like Save My Fat, it is collected, processed according to cryopreservation protocols, and stored at ultra-low temperatures for potential future use. The banking process is designed for long-term stability, not for immediate microfragmentation and injection.
There are currently no US clinical trials or approved indications where patients retrieve banked adipose from a private bank and have it processed into MFAT for treatment. Could a future product sponsor design a protocol that uses banked tissue as starting material? In theory, yes, but that would require a formal IND application, GMP manufacturing controls, and regulatory approval. No such product exists today, and banking does not guarantee future access to MFAT or any other specific procedure. For more on how banking differs from same-day treatment clinics, see our comparison guide.
Red Flags Around MFAT and “Fat Stem Cell” Marketing
The gap between what MFAT trials have shown and what some clinics advertise is significant. Watch for these warning signs.
Calling MFAT an “FDA-approved stem cell injection.” No MFAT product is FDA-approved for any indication. Clinics that market MFAT as approved or “FDA-cleared” for OA or any disease are misrepresenting its regulatory status.
Promising cartilage regrowth, arthritis reversal, or guaranteed avoidance of joint replacement. No RCT has demonstrated that MFAT regenerates cartilage or reverses structural OA damage. Claims of guaranteed outcomes are not supported by the evidence.
Bundling MFAT with IV infusions, exosome injections, or multi-site injections. Combining MFAT with other unapproved products without trial registration or IND coverage compounds both the regulatory and safety concerns.
No ClinicalTrials.gov registration, no IRB oversight, and high out-of-pocket costs. Legitimate clinical trials are registered, reviewed by an institutional review board, and typically do not charge patients thousands of dollars for experimental treatments. If a clinic offers MFAT outside of a registered trial and without IND authorization, patients should ask detailed questions about regulatory compliance.
Marketing MFAT as “stem cell therapy.” MFAT contains some cells with stem-like properties, but it is primarily a tissue fragment product, not a purified stem cell preparation. Calling it “stem cell therapy” can mislead patients about what they are receiving.
For a broader checklist, see our guide on how to spot fake stem cell clinics.
How to Talk to Your Doctor If MFAT Is Offered
If a provider recommends an MFAT procedure, or if you are considering one based on your own research, these questions can help you evaluate the offer.
“Is this procedure part of a registered clinical trial with a ClinicalTrials.gov number, or is it being performed off-protocol?” This is the single most important question. A registered trial means there is an approved protocol, regulatory oversight, and systematic data collection.
“What is the evidence level for this indication, and what outcomes should I realistically expect?” Ask the provider to cite specific RCTs and explain the sample sizes, follow-up durations, and whether the results were compared to placebo or active controls.
“How is this product regulated in the United States?” A provider who understands the regulatory landscape should be able to explain where MFAT falls under FDA’s HCT/P framework and why most orthopedic uses are considered non-homologous.
“What are my other options, including physical therapy, weight management, bracing, or surgical intervention?” MFAT should be considered in the context of the full range of OA management strategies, not as a replacement for proven approaches.
“What are the total costs, and does insurance cover any portion?” Most MFAT procedures are paid out of pocket. Understanding the financial commitment alongside the evidence level helps patients make informed decisions.
Where MFAT Fits in the Broader Adipose Landscape
MFAT is one of several adipose-based strategies currently being researched for orthopedic and regenerative medicine applications. Others include SVF, cultured ADSCs, simple fat grafting, and adipose-derived exosomes. Each has different processing methods, different regulatory classifications, and different levels of clinical evidence. None are FDA-approved for treating osteoarthritis or systemic diseases.
Adipose tissue banking sits apart from all of these point-of-care procedures. Banking is about preserving tissue at its current biological state for potential future use in regulated pathways, whether that involves MFAT, cultured cells, or products that have not yet been developed. It is a proactive step, not a treatment itself. For patients interested in preserving tissue for themselves and potentially eligible family members, banking provides optionality without making claims about specific future procedures.
To learn more about banking, the science behind cryopreservation, or how to connect with a participating provider, explore our educational resources or contact our team.
Frequently Asked Questions
Is MFAT a stem cell treatment? Not exactly. MFAT is a mechanically processed tissue product that retains adipose fragments and the cells naturally found within fat, including some cells with regenerative properties. It is not a purified or expanded stem cell preparation. Calling it “stem cell therapy” oversimplifies what the product contains and can create misleading expectations.
Is MFAT FDA-approved for knee osteoarthritis? No. There are no FDA-approved MFAT products for knee osteoarthritis, tendon injuries, diabetic foot wounds, or any other indication. MFAT has been studied in clinical trials, but study data alone do not constitute regulatory approval.
Do MFAT trials show cartilage regrowth? No published randomized trial has demonstrated that MFAT regenerates articular cartilage or reverses structural OA progression. Some trials have reported improved MRI findings, but these are surrogate markers, not confirmed evidence of cartilage restoration. The primary outcomes that show improvement in some trials are patient-reported pain and function scores.
Can my banked fat be turned into MFAT later? There are no current clinical trials or approved protocols in the United States that use previously banked adipose tissue to produce MFAT for injection. All published MFAT trials use same-day harvest and processing. A future product could theoretically be designed to use banked tissue as starting material, but that would require IND-level development and regulatory approval. Banking preserves optionality but does not guarantee access to any specific procedure.
Is MFAT safer than PRP or hyaluronic acid injections? Published trials and systematic reviews report that MFAT has a safety profile comparable to PRP in the short to mid-term, with no treatment-related serious adverse events reported in most studies. However, MFAT requires a liposuction harvest, which carries its own procedural risks (bruising, swelling, infection) that do not apply to PRP or hyaluronic acid injections. Long-term safety data beyond two years remain limited.
Key Takeaways
MFAT is a mechanically processed adipose tissue product studied in randomized trials for knee OA and diabetic foot wounds, but it is not FDA-approved for any indication.
Some RCTs show MFAT outperforming saline in pain and function at one year, while others show no superiority over placebo at two years. MFAT and PRP produce comparable results in head-to-head trials. Evidence is early, sample sizes are modest, and structural disease modification remains unproven.
FDA regulation of MFAT depends on both manipulation level and intended use. Most orthopedic applications are considered non-homologous, placing MFAT under drug and biologic oversight rather than the simpler HCT/P pathway.
MFAT is a same-day, point-of-care procedure. It is not the same as adipose tissue banking, and banked tissue is not currently used in any MFAT protocol.
Patients should ask specific questions about trial registration, evidence level, regulatory status, and alternative treatments before agreeing to any MFAT procedure.
Learn More
Before contacting Save My Fat: Adipose tissue banking is a preservation service that stores tissue for potential future use, not a treatment or guarantee of access to MFAT procedures, clinical trials, or any specific medical product. No MFAT or adipose-derived product is FDA-approved for disease treatment. Patients should discuss any questions about MFAT, orthobiologics, or investigational therapies with their own physicians.
To explore current research areas, see the Research Areas overview or the Joint and Orthopedic page.
To understand how banking differs from same-day procedures, read Banking vs. Same-Day Treatment Clinics.
For questions about logistics and costs, visit How Stem Cell Banking Works or the Pricing page.
To schedule a consultation, contact Save My Fat by visiting the Contact page.
Last Updated: March 30, 2026.
